作者
F Wang, XL Wei, FH Wang, N Xu, L Shen, GH Dai, XL Yuan, Y Chen, SJ Yang, JH Shi, XC Hu, XY Lin, QY Zhang, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu
发表日期
2019/9/1
期刊
Annals of Oncology
卷号
30
期号
9
页码范围
1479-1486
出版商
Elsevier
简介
Background
High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.
Patients and methods
We reported on the AGC cohort of phase Ib/II trial evaluating the safety and activity of toripalimab in patients with AGC, oesophageal squamous cell carcinoma, nasopharyngeal carcinoma and head and neck squamous cell carcinoma. In cohort 1, 58 chemo-refractory AGC patients received toripalimab (3 mg/kg d1, Q2W) as a monotherapy. In cohort 2, 18 chemotherapy-naive AGC patients received toripalimab (360 mg d1, Q3W) with oxaliplatin 130 mg/m2 qd, d1, capecitabine 1000 mg/m2 b …
学术搜索中的文章
F Wang, XL Wei, FH Wang, N Xu, L Shen, GH Dai… - Annals of Oncology, 2019